Absence of genotypic drug resistance and presence of several naturally occurring polymorphisms of human immunodeficiency virus-1 CRF06-cpx in treatment-naive patients in Estonia

Journal of Medical Virology

Volumn 81, Issue 6, 2009, Pages 953-958

  Avi, Radko ^a,e   Huik, Kristi ^a   Sadam, Maarja ^a   Karki, Tonis ^a   Krispin, Tonu ^a   Ainsalu, Külliki ^b   Paap, Piret ^c   Schmidt, Jelena ^d   Nikitina, Natalia ^d   Lutsar, Irja ^a  

^a UNIVERSITY OF TARTU   (Estonia)

^b TARTU UNIVERSITY HOSPITAL   (Estonia)

^c Hospital of Tartu Prison   (Estonia)

^d Ida Viru Central Hospital   (Estonia)

^e UNIVERSITY OF TARTU   (Estonia)

Author keywords

Drug resistance mutation; Natural polymorphism; Protease; Revertase

Indexed keywords

ANTIRETROVIRUS AGENT; GENOMIC RNA; PROTEINASE; RNA DIRECTED DNA POLYMERASE; VIRUS ENVELOPE PROTEIN; VIRUS RNA;

ADULT; ANTIVIRAL RESISTANCE; ARTICLE; CLINICAL STUDY; ESTONIA; FEMALE; GENE MUTATION; GENETIC POLYMORPHISM; GENOTYPE; HETEROSEXUALITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; PHYLOGENY; PLASMA; RNA SEQUENCE; UNINDEXED SEQUENCE; CLASSIFICATION; DNA SEQUENCE; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; ISOLATION AND PURIFICATION; MISSENSE MUTATION; MOLECULAR GENETICS; SEQUENCE HOMOLOGY; VIROLOGY;

HUMAN IMMUNODEFICIENCY VIRUS 1;

ADULT; DRUG RESISTANCE, VIRAL; ENV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; ESTONIA; FEMALE; GENOTYPE; HIV INFECTIONS; HIV PROTEASE; HIV REVERSE TRANSCRIPTASE; HIV-1; HUMANS; MALE; MOLECULAR SEQUENCE DATA; MUTATION, MISSENSE; PHYLOGENY; POLYMORPHISM, GENETIC; RNA, VIRAL; SEQUENCE ANALYSIS, DNA; SEQUENCE HOMOLOGY;

EID: 66449115343     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.21482     Document Type: Article

References (28)

1. Adojaan M, Kivisild T, Mannik A, Krispin T, Ustina V, Zilmer K, Liebert E, Jaroslavtsev N, Priimagi L, Tefanova V, Schmidt J, Krohn K, Villems R, Salminen M, Ustav M. 2005. Predominance of a rare type of HIV-1 in Estonia. J Acquir Immune Defic Syndr 39:598-605. (Pubitemid 41098477)
2. Ariyoshi K, Matsuda M, Miura H, Tateishi S, Yamada K, Sugiura W. 2003. Patterns of point mutations associated with antiretroviral drug treatment failure in CRF01-AE (subtype E) infection differ from subtype B infection. J Acquir Immune Defic Syndr 33:336-342. (Pubitemid 36859059)
3. Bobkov A, Kazennova E, Selimova L, Bobkova M, Khanina T, Ladnaya N, Kravchenko A, Pokrovsky V, Cheingsong-Popov R, Weber J. 1998. A sudden epidemic of HIV type 1 among injecting drug users in the former Soviet Union: Identification of subtype A, subtype B, and novel gagA/envB recombinants. AIDS Res Hum Retroviruses 14:669-676. (Pubitemid 28244047)
4. Cane PA, de Ruiter A, Rice P, Wiselka M, Fox R, Pillay D. 2001. Resistance-associated mutations in the human immunodeficiency virus type 1 subtype c protease gene from treated and untreated patients in the United Kingdom. J Clin Microbiol 39:2652-2654. (Pubitemid 32606251)
5. Geretti AM. 2006. HIV-1 subtypes: Epidemiology and significance for HIV management. Curr Opin Infect Dis 19:1-7. (Pubitemid 43032432)
6. Gonzalez LM, Brindeiro RM, Aguiar RS, Pereira HS, Abreu CM, Soares MA, Tanuri A. 2004a. Impact of nelfinavir resistance mutations on in vitro phenotype, fitness, and replication capacity of human immunodeficiency virus type 1 with subtype B and C proteases. Antimicrob Agents Chemother 48:3552-3555. (Pubitemid 39129358)
7. Gonzalez R, Masquelier B, Fleury H, Lacroix B, Troesch A, Vernet G, Telles JN. 2004b. Detection of human immunodeficiency virus type 1 antiretroviral resistance mutations by high-density DNA probe arrays. J Clin Microbiol 42:2907-2912. (Pubitemid 38938035)
8. Grossman Z, Paxinos EE, Averbuch D, Maayan S, Parkin NT, Engelhard D, Lorber M, Istomin V, Shaked Y, Mendelson E, Ram D, Petropoulos CJ, Schapiro JM. 2004. Mutation D30N is not preferentially selected by human immunodeficiency virus type 1 subtype C in the development of resistance to nelfinavir. Antimicrob Agents Chemother 48:2159-2165. (Pubitemid 38691614)
9. Kantor R, Katzenstein DA, Efron B, Carvalho AP, Wynhoven B, Cane P, Clarke J, Sirivichayakul S, Soares MA, Snoeck J, Pillay C, Rudich H, Rodrigues R, Holguin A, Ariyoshi K, Bouzas MB, Cahn P, Sugiura W, Soriano V, Brigido LF, Grossman Z, Morris L, Vandamme AM, Tanuri A, Phanuphak P, Weber JN, Pillay D, Harrigan PR, Camacho R, Schapiro JM, Shafer RW. 2005. Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: Results of a global collaboration. PLoSMed 2:e112. (Pubitemid 40721078)
10. Lawrence P, Lutz MF, Saoudin H, Fresard A, Cazorla C, Fascia P, Pillet S, Pozzetto B, Lucht F, Bourlet T. 2006. Analysis of polymorphism in the protease and reverse transcriptase genes of HIV type 1 CRF02-AG subtypes from drug-naive patients from Saint-Etienne, France. J Acquir Immune Defic Syndr 42:396-404. (Pubitemid 44050885)
11. Liitsola K, Laukkanen T, Denisova A, Grishkevichius A, Smolskaja T, Ustina V, Vlasov N, Leinikki P, Salminen MO. 1996. Genetic characterization of HIV-1 strains in the Baltic countries and Russia. Scand J Infect Dis 28:537-541. (Pubitemid 27092389)
12. Liitsola K, Holm K, Bobkov A, Pokrovsky V, Smolskaya T, Leinikki P, Osmanov S, Salminen M. 2000. An AB recombinant and its parental HIV type 1 strains in the area of the former Soviet Union: Low requirements for sequence identity in recombination. UNAIDS Virus Isolation Network. AIDS Res Hum Retroviruses 16:1047-1053. (Pubitemid 30461044)
13. Monno L, Brindicci G, Lo Caputo S, Punzi G, Scarabaggio T, Riva C, Di Bari C, Pierotti P, Saracino A, Lagioia A, Mazzotta F, Balotta C, Angarano G. 2005. HIV-1 subtypes and circulating recombinant forms (CRFs) from HIV-infected patients residing in two regions of central and southern Italy. J Med Virol 75:483-490. (Pubitemid 40293514)
14. Montavon C, Toure-Kane C, Nkengasong JN, Vergne L, Hertogs K, Mboup S, Delaporte E, Peeters M. 2002. CRF06-cpx: A new circulating recombinant form of HIV-1 in West Africa involving subtypes A, G, K, and J. J Acquir Immune Defic Syndr 29:522-530. (Pubitemid 34456345)
15. Ndembi N, Abraha A, Pilch H, Ichimura H, Mbanya D, Kaptue L, Salata R, Arts EJ. 2008. Molecular characterization of HIV-1 and HIV-2 in Yaounde, Cameroon: Evidence of major drug resistance mutations in newly diagnosed non-B infected patients. J Clin Microbiol 46:177-184.
16. Ode H, Neya S, Hata M, Sugiura W, Hoshino T. 2006. Computational simulations of HIV-1 proteases - Multi-drug resistance due to nonactive site mutation L90M. J Am Chem Soc 128:7887-7895. (Pubitemid 43945729)
17. Ode H, Matsuyama S, Hata M, Hoshino T, Kakizawa J, Sugiura W. 2007a. Mechanism of drug resistance due to N88S in CRF01-AE HIV-1 protease, analyzed by molecular dynamics simulations. J Med Chem 50:1768-1777. (Pubitemid 46626588)
18. Ode H, Matsuyama S, Hata M, Neya S, Kakizawa J, Sugiura W, Hoshino T. 2007b. Computational characterization of structural role of the non-active site mutation M36I of human immunodeficiency virus type 1 protease. J Mol Biol 370:598-607. (Pubitemid 46901071)
19. Perno CF, Cozzi-Lepri A, Balotta C, Forbici F, Violin M, Bertoli A, Facchi G, Pezzotti P, Cadeo G, Tositti G, Pasquinucci S, Pauluzzi S, Scalzini A, Salassa B, Vincenti A, Phillips AN, Dianzani F, Appice A, Angarano G, Monno L, Ippolito G, Moroni M, d' Arminio Monforte A. 2001. Secondary mutations in the protease region of human immunodeficiency virus and virologic failure in drug-naive patients treated with protease inhibitor-based therapy. J Infect Dis 184:983-991.
20. Roudinskii NI, Sukhanova AL, Kazennova EV, Weber JN, Pokrovsky VV, Mikhailovich VM, Bobkov AF. 2004. Diversity of human immunodeficiency virus type 1 subtype A and CRF03-AB protease in Eastern Europe: Selection of the V77I variant and its rapid spread in injecting drug user populations. J Virol 78:11276-11287. (Pubitemid 39299667)
21. Tamura K, Dudley J, Nei M, Kumar S. 2007. MEGA4: Molecular evolutionary genetics analysis (MEGA) software version 4.0. Mol Biol Evol 24:1596-1599. (Pubitemid 47236692)
22. Ustina V, Zilmer K, Tammai L, Raukas M, Andersson A, Lilja E, Albert J. 2001. Epidemiology of HIV in Estonia. AIDS Res Hum Retroviruses 17:81-85. (Pubitemid 32096428)
23. Uuskula A, Kalikova A, Zilmer K, Tammai L, DeHovitz J. 2002. The role of injection drug use in the emergence of human immunodeficiency virus infection in Estonia. Int J Infect Dis 6:23-27. (Pubitemid 34716684)
24. van de Vijver DA, Wensing AM, Angarano G, Asjo B, Balotta C, Boeri E, Camacho R, Chaix ML, Costagliola D, De Luca A, Derdelinckx I, Grossman Z, Hamouda O, Hatzakis A, Hemmer R, Hoepelman A, Horban A, Korn K, Kucherer C, Leitner T, Loveday C, MacRae E, Maljkovic I, de Mendoza C, Meyer L, Nielsen C, Op de Coul EL, Ormaasen V, Paraskevis D, Perrin L, Puchhammer-Stockl E, Ruiz L, Salminen M, Schmit JC, Schneider F, Schuurman R, Soriano V, Stanczak G, Stanojevic M, Vandamme AM, Van Laethem K, Violin M, Wilbe K, Yerly S, Zazzi M, Boucher CA. 2006. The calculated genetic barrier for antiretroviral drug resistance substitutions is largely similar for different HIV-1 subtypes. J Acquir Immune Defic Syndr 41:352-360.
25. Vergne L, PeetersM, Mpoudi-Ngole E, Bourgeois A, Liegeois F, Toure-Kane C, Mboup S, Mulanga-Kabeya C, Saman E, Jourdan J, Reynes J, Delaporte E. 2000. Genetic diversity of protease and reverse transcriptase sequences in non-subtype-B human immunodeficiency virus type 1 strains: Evidence of many minor drug resistance mutations in treatment-naive patients. J Clin Microbiol 38:3919-3925. (Pubitemid 32233182)
26. Wegner SA, Brodine SK, Mascola JR, Tasker SA, Shaffer RA, Starkey MJ, Barile A, Martin GJ, Aronson N, Emmons WW, Stephan K, Bloor S, Vingerhoets J, Hertogs K, Larder B. 2000. Prevalence of genotypic and phenotypic resistance to anti-retroviral drugs in a cohort of therapy-naive HIV-1 infected US military personnel. AIDS 14:1009-1015. (Pubitemid 30336062)
27. Weinstock HS, Zaidi I, Heneine W, Bennett D, Garcia-Lerma JG, Douglas JM, Jr., LaLota M, Dickinson G, Schwarcz S, Torian L, Wendell D, Paul S, Goza GA, Ruiz J, Boyett B, Kaplan JE. 2004. The epidemiology of antiretroviral drug resistance among drug-naive HIV-1-infected persons in 10 US cities. J Infect Dis 189:2174-2180. (Pubitemid 38757188)
28. Zetterberg V, Ustina V, Liitsola K, Zilmer K, Kalikova N, Sevastianova K, Brummer-Korvenkontio H, Leinikki P, Salminen MO. 2004. Two viral strains and a possible novel recombinant are responsible for the explosive injecting drug use-associated HIV type 1 epidemic in Estonia. AIDS Res Hum Retroviruses 20:1148-1156. (Pubitemid 39557865)